Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Parsons not on ONCY board for licensing & biobuck deals

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Aug 20, 2022 7:09pm

240 Views

Post# 34909642

RE:Parsons not on ONCY board for licensing & biobuck deals

Agreed 100% that Parsons is there for one reason...to negotiate a buyout, most likely with Pfizer. Coffey just seems to consciously avoid any mention of the word buyout, obviously & appropriately playing his cards close to his chest. Anxious & exciting times ahead, as Onc may be acquired sometime in Q4 !

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec